241 related articles for article (PubMed ID: 36322632)
1. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak MA; Rodrigues Mantuano N; Kirchhammer N; Sanin DE; Jacob F; Coelho R; Everest-Dass AV; Wang J; Trefny MP; Monaco G; Bärenwaldt A; Gray MA; Petrone A; Kashyap AS; Glatz K; Kasenda B; Normington K; Broderick J; Peng L; Pearce OMT; Pearce EL; Bertozzi CR; Zippelius A; Läubli H
Sci Transl Med; 2022 Nov; 14(669):eabj1270. PubMed ID: 36322632
[TBL] [Abstract][Full Text] [Related]
2. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
3. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
4. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy.
Wu Q; Wei X; Chen F; Huang M; Zhang S; Zhu L; Zhou L; Yang C; Song Y
Angew Chem Int Ed Engl; 2023 Dec; 62(52):e202312609. PubMed ID: 37955317
[TBL] [Abstract][Full Text] [Related]
6. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
7. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.
Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
Blood Adv; 2022 Jun; 6(11):3352-3366. PubMed ID: 35294519
[TBL] [Abstract][Full Text] [Related]
8. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
9. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.
Beatson R; Tajadura-Ortega V; Achkova D; Picco G; Tsourouktsoglou TD; Klausing S; Hillier M; Maher J; Noll T; Crocker PR; Taylor-Papadimitriou J; Burchell JM
Nat Immunol; 2016 Nov; 17(11):1273-1281. PubMed ID: 27595232
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
11. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Smith BAH; Deutzmann A; Correa KM; Delaveris CS; Dhanasekaran R; Dove CG; Sullivan DK; Wisnovsky S; Stark JC; Pluvinage JV; Swaminathan S; Riley NM; Rajan A; Majeti R; Felsher DW; Bertozzi CR
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215376120. PubMed ID: 36897988
[TBL] [Abstract][Full Text] [Related]
12. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
Rodriguez E; Boelaars K; Brown K; Eveline Li RJ; Kruijssen L; Bruijns SCM; van Ee T; Schetters STT; Crommentuijn MHW; van der Horst JC; van Grieken NCT; van Vliet SJ; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
Nat Commun; 2021 Feb; 12(1):1270. PubMed ID: 33627655
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
14. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
15. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
[TBL] [Abstract][Full Text] [Related]
16. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
17. Sialylation acts as a checkpoint for innate immune responses in the central nervous system.
Klaus C; Liao H; Allendorf DH; Brown GC; Neumann H
Glia; 2021 Jul; 69(7):1619-1636. PubMed ID: 33340149
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
19. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
[TBL] [Abstract][Full Text] [Related]
20. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
